A number of research firms have changed their ratings and price targets for Hikma Pharmaceuticals PLC (LON: HIK):

  • 11/15/2017 – Hikma Pharmaceuticals PLC had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 1,390 ($18.28) price target on the stock.
  • 11/10/2017 – Hikma Pharmaceuticals PLC had its price target lowered by analysts at J P Morgan Chase & Co from GBX 1,250 ($16.44) to GBX 1,000 ($13.15). They now have a “neutral” rating on the stock.
  • 11/10/2017 – Hikma Pharmaceuticals PLC had its price target lowered by analysts at from GBX 1,060 ($13.94) to GBX 865 ($11.38). They now have a “reduce” rating on the stock.
  • 11/9/2017 – Hikma Pharmaceuticals PLC had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 1,390 ($18.28) price target on the stock.
  • 11/9/2017 – Hikma Pharmaceuticals PLC was upgraded by analysts at Numis Securities Ltd to a “buy” rating. They now have a GBX 1,300 ($17.10) price target on the stock.
  • 11/9/2017 – Hikma Pharmaceuticals PLC had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a GBX 1,045 ($13.74) price target on the stock.
  • 11/9/2017 – Hikma Pharmaceuticals PLC had its price target lowered by analysts at Stifel Nicolaus from GBX 1,320 ($17.36) to GBX 1,000 ($13.15). They now have a “hold” rating on the stock.
  • 10/31/2017 – Hikma Pharmaceuticals PLC had its “hold” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 1,390 ($18.28) price target on the stock.
  • 10/6/2017 – Hikma Pharmaceuticals PLC had its price target lowered by analysts at J P Morgan Chase & Co from GBX 1,500 ($19.73) to GBX 1,250 ($16.44). They now have a “neutral” rating on the stock.
  • 9/29/2017 – Hikma Pharmaceuticals PLC had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co.

Hikma Pharmaceuticals PLC (LON:HIK) opened at GBX 1,054 ($13.86) on Wednesday. Hikma Pharmaceuticals PLC has a twelve month low of GBX 906.50 ($11.92) and a twelve month high of GBX 2,346 ($30.86).

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.